[Changes in iron metabolism and erythropoietin requirements after the switch from ferric gluconate to iron saccharose. Is it worth the increased expense?].
Rodríguez Palomares
J R
JR
Fanlo
B
B
Albarracín
C
C
Junquera
E
E
D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy* / Q000191:economics / Q000209:etiology; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004921:Erythropoietin / Q000191:economics / Q000627:therapeutic use; D005260:Female; D005290:Ferric Compounds / Q000191:economics / Q000627:therapeutic use*; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; D006801:Humans; D007501:Iron / Q000378:metabolism* / Q000493:pharmacokinetics; D007676:Kidney Failure, Chronic / Q000097:blood / Q000191:economics / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects* / Q000191:economics; D013030:Spain; D013395:Sucrose / Q000191:economics / Q000627:therapeutic use*
D005290:Ferric Compounds; D004921:Erythropoietin; D013395:Sucrose; D007501:Iron; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; C035552:ferric gluconate